Effect of Bevacizumab combined with Cisplatin in the treatment of gastric cancer with ascites
TANG Xiaolong1 CHEN Xufeng1 ZHENG Yang1 YANG Shenglan1 CHEN Liang2
1.Department of Digestive System, No.904 Hospital of PLA Joint Service Support Force, Jiangsu Province, Wuxi 214000, China;
2.Department of Internal Medicine-Cardiovascular, No.904 Hospital of PLA Joint Service Support Force, Jiangsu Province, Wuxi 214000, China
Abstract：Objective To observe the efficacy of Bevacizumab combined with Cisplatin in the treatment of gastric cancer with ascites. Methods A total of 102 patients with gastric cancer and ascites admitted to the No.904 Hospital of PLA Joint Service Support Force from June 2017 to June 2020 were selected. The patients were divided into control group and study group by random number method, with 51 cases in each group. The control group was given Cisplatin intraperitoneal administration, and the research group was combined with Bevacizumab on the basis of the control group, with 21 days as a treatment cycle, a total of two cycles of treatment. The efficacy of the two groups was compared. The levels of tumor markers (carbohydrate antigen [CA] 125, carcinoembryonic antigen [CEA], CA199), and mRNA expression of matrix metalloproteinase (MMP)-2, Gil1, and MMP-9 in ascites were compared between the two groups. The incidence of adverse reactions in the two groups was recorded. Results The objective remission rate and disease control rate in the study group were higher than those in the control group, and the differences were statistically significant (P ＜ 0.05). After two cycles of treatment, the levels of CEA, CA125, and CA199 in ascites in both groups were lower than before treatment, and those in the study group were lower than those in the control group, with statistical significance (P ＜ 0.05). After two cycles of treatment, the mRNA expressions of MMP-2, Gil1, and MMP-9 in ascites in both groups were lower than before treatment, and those in the study group were lower than those in the control group, with statistical significance (P ＜ 0.05). There was no significant difference in the total incidence of adverse reaction between the two groups (P ＞ 0.05). Conclusion Intraperitoneal administration of Bevacizumab combined with Cisplatin in the treatment of ascites in gastric cancer can effectively alleviate the progression of ascites with reliable efficacy.
汤小龙1 陈旭峰1 郑杨1 杨胜兰1 陈亮2. 贝伐珠单抗联合顺铂腹腔给药治疗胃癌腹水的效果[J]. 中国医药导报, 2021, 18(23): 88-91,107.
TANG Xiaolong1 CHEN Xufeng1 ZHENG Yang1 YANG Shenglan1 CHEN Liang2. Effect of Bevacizumab combined with Cisplatin in the treatment of gastric cancer with ascites. 中国医药导报, 2021, 18(23): 88-91,107.
京公网安备 11010502046598号